Milestone Pharmaceuticals Files 8-K on Financials
Ticker: MIST · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1408443
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Milestone Pharma filed an 8-K on 8/12/25 for financial updates.
AI Summary
On August 12, 2025, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Milestone Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is crucial for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial reporting and does not contain any immediately alarming information.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- 1111 Dr. Frederik-Philips Boulevard (location) — Principal executive offices address
- Montreal, Quebec (location) — Principal executive offices city and state
- H4M 2X6 (location) — Principal executive offices zip code
- (514) 336-0444 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K?
The provided excerpt states the 8-K concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures or content of these reports.
When was the earliest event reported in this filing?
The earliest event reported is dated August 12, 2025.
What is the principal executive office address for Milestone Pharmaceuticals Inc.?
The principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Quebec, H4M 2X6.
What is Milestone Pharmaceuticals Inc.'s telephone number?
The company's telephone number is (514) 336-0444.
What is the SIC code for Milestone Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Milestone Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2025-08-12 07:16:26
Filing Documents
- tm2523169d1_8k.htm (8-K) — 24KB
- tm2523169d1_ex99-1.htm (EX-99.1) — 79KB
- tm2523169d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-25-076468.txt ( ) — 282KB
- mist-20250812.xsd (EX-101.SCH) — 3KB
- mist-20250812_lab.xml (EX-101.LAB) — 33KB
- mist-20250812_pre.xml (EX-101.PRE) — 22KB
- tm2523169d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On August 12, 2025, Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025, which also provided a regulatory and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 12, 2025 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. By: /s/Amit Hasija Amit Hasija Chief Financial Officer Dated: August 12, 2025